Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma

References

• Hodi FS, O'Day SJ, McDermott DF, Weber RW. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23. doi:10.105/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen T-T, Berman DM, Wolchok JD. Pooled analysis of long-term survival data from phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2016;33:1889–94. doi:10.120/JCO.2014.56.2736.
   Google Scholar
• Di Giacomo AM, Calabro L, Danielli R, Fonsatti E, Bertocci E, Pesce I, Fazio C, Cutaia O, Giannarelli D, Miracco C, et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 m/kg within an expanded access programme. Cancer Immunol Immunother. 2013;62:1021–8. doi:10.100/s00262-013-1418-6.
   PubMed Web of Science ®Google Scholar
• Martens A, Wistuba-Hamprecht K, Foppen MG, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dréno B, Capone M, et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res. 2016;22:2908–18. doi:10.115/1078-0432.CCR-15-2412.
   PubMed Web of Science ®Google Scholar
• Callahan MK, Wolchok JD, Allison JP. Anti–CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol. 2010;37:473–84. doi:10.105/j.seminoncol.2010.09.001.
   PubMed Web of Science ®Google Scholar
• Kitano S, Tsuji T, Liu C, Hirschhorn-Cymerman D, Kyi C, Mu Z, Allison JP, Gnjatic S, Yuan JD, Wolchok JD. Enhancement of tumor-reactive cytotoxic CD4+ T-cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res. 2013;1:235–44. doi:10.115/2326-6066.CIR-13-0068.
   Google Scholar
• Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logothetis C, et al. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci USA. 2009;106:2729–34. doi:10.107/pnas.0813175106.
   PubMed Web of Science ®Google Scholar
• Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA. 2011;108:16723–8. doi:10.107/pnas.1110814108.
   PubMed Web of Science ®Google Scholar
• Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Jacquelot N, Vimond N, Chouaib S, Mateus C, et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 2015;25:208–24. doi:10.103/cr.2015.3.
   PubMed Web of Science ®Google Scholar
• Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: Current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta. 2012;1820:940–8. doi:10.101/j.bbagen.2012.03.017.
   PubMed Web of Science ®Google Scholar
• Mannavola F, Tucci M, Felici C, Stucci S, Silvestris F. miRNAs in melanoma: a defined role in tumor progression and metastasis. Exp Rev Clin Immunol. 2015;12:79–89. doi:10.158/1744666X.2016.1100965.
   Google Scholar
• Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Curry WT, Carter BS, Krichevsky AM, Breakefield XO. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10:1470–6. doi:10.103/ncb1800.
   PubMed Web of Science ®Google Scholar
• Hoshino A, Costa-Silva B, Shen T-L, Rodrigues G, Hashimoto A, Mark MT, Molina H, Kohsaka S, Di Giannatale A, Ceder S, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527:329–35. doi:10.103/nature15756.
   PubMed Web of Science ®Google Scholar
• Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar CM, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18:883–91. doi:10.103/nm.2753.
   PubMed Web of Science ®Google Scholar
• Logozzi M, De Milito A, Lugini L, Borghi M, Calabro L, Spada M, Perdicchio M, Marino ML, Federici C, Iessi E, et al. High levels of exosomes expressing CD63 and Caveolin-1 in plasma of melanoma patients. PLoS ONE. 2009;4:e5219–10. doi:10.137/journal.pone.0005219.
   PubMed Web of Science ®Google Scholar
• Lazar I, Clement E, Ducoux Petit M, Denat L, Soldan V, Dauvillier S, Balor S, Burlet Schiltz O, Larue L, Muller C, et al. Proteome characterization of melanoma exosomes reveals a specific signature for metastatic cell lines. Pigment Cell Melanoma Res. 2015;28:464–75. doi:10.111/pcmr.12380.
   PubMed Web of Science ®Google Scholar
• Zijlstra C, Stoorvogel W. Prostasomes as a source of diagnostic biomarkers for prostate cancer. JCI. 2016;126:1144–51. doi:10.117/JCI81128.
   Google Scholar
• Properzi F, Logozzi M, Fais S. Exosomes: the future of biomarkers in medicine. Biomarkers Med. 2013;7:769–78. doi:10.221/bmm.13.63.
   PubMed Web of Science ®Google Scholar
• Redzic J, Ung T, Graner M. Glioblastoma extracellular vesicles: reservoirs of potential biomarkers. Pharm Pers Med. 2014;7:65–13.
   Google Scholar
• Adams M, Navabi H, Croston D, Coleman S, Tabi Z, Clayton A, Jasani B, Mason MD. The rationale for combined chem/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine. 2005;23:2374–8. doi:10.101/j.vaccine.2005.01.014.
   PubMed Web of Science ®Google Scholar
• Pitt JM, André F, Amigorena S, Soria J-C, Eggermont A, Kroemer G, Zitvogel L. Dendritic cell–derived exosomes for cancer therapy. JCI. 2016;126:1224–32. doi:10.117/JCI81137.
   Google Scholar
• Escudier B, Dorval T, Chaput N, André F, Caby M-P, Novault S, Flament C, Leboulaire C, Borg C, Amigorena S, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med. 2005;3:10. doi:10.118/1479-5876-3-10.
   PubMed Web of Science ®Google Scholar
• Tucci M, Stucci S, Passarelli A, D'Oronzo S, Silvestris F. Everolimus restrains the IL-17 A-dependent osteoclast-like transdifferentiation of dendritic cells in multiple myeloma. Exp Hematol. 2017;47:48–53. doi:10.101/j.exphem.2016.10.004.
   Google Scholar
• Tucci M, Stucci S, Savonarola A, Ciavarella S, Cafforio P, Dammacco F, Silvestris F. Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17 A stimulation. Br J Haematol. 2013;161:821–31. doi:10.111/bjh.12333.
   Google Scholar
• Théry C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. 5th ed. Hoboken (NJ, USA): John Wiley & Sons, Inc; 2006.
   Google Scholar
• Lötvall J, Hill AF, Hochberg F, Buzàs EI, Di Vizio D, Gardiner C, Gho YS, Kurochin IV, Mathivanan S, Quesenberry P, Sahoo S, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement for the international society for extracellular vesicles. J Extracell Vesic. 2014;3:26913. doi:10.340/jev.v3.26913.
   PubMedGoogle Scholar
• Record M, Carayon K, Poirot M, Silvente-Poirot S. Exosomes as new vesicular lipid transporters involved in cell-cell communication and various pathophysiologies. Bioch Biophys Acta. 2014;1841:108–20.
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30. doi:10.105/NEJMoa1412082.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373:1627–39. doi:10.105/NEJMoa1507643.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–13. doi:10.105/NEJMoa1510665.
   PubMed Web of Science ®Google Scholar
• Tucci M, Stucci S, Passarelli A, Giudice G, Dammacco F, Silvestris F. The immune escape in melanoma: role of the impaired dendritic cell function. Exp Rev Clin Immunol. 2014;10:1395–404. doi:10.158/1744666X.2014.955851.
   PubMed Web of Science ®Google Scholar
• Wistuba-Hamprecht K, Martens A, Heubach F, Romano E, Foppen MG, Yuan J, Postow M, Wong P, Mallardo D, Schilling B, et al. Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. Eur J Cancer. 2017;73:61–70. doi:10.101/j.ejca.2016.12.011.
   PubMed Web of Science ®Google Scholar
• Wistuba-Hamprecht K, Martens A, Haehnel K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dréno B, et al. Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. Eur J Cancer. 2016;64:116–26. doi:10.101/j.ejca.2016.06.001.
   Google Scholar
• Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res. 2013;19:1009–20. doi:10.115/1078-0432.CCR-12-2982.
   PubMed Web of Science ®Google Scholar
• Gardner D, Jeffery LE, Sansom DM. Understanding the CD2/CTLA-4 (CD152) pathway and its implications for costimulatory blockade. Am J Transpl. 2014;14:1985–91. doi:10.111/ajt.12834.
   PubMed Web of Science ®Google Scholar
• Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C, Sharma P. CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA. 2008;105:14987–92. doi:10.107/pnas.0806075105.
   PubMed Web of Science ®Google Scholar
• Four M, Cacheux V, Tempier A, Platero D, Fabbro M, Marin G, Leventoux N, Rigau V, Costes-Martineau V, Szablewski V. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival. Hematol Oncol. December 13 2016. doi:10.100/hon.2375. [Epub ahead of print ].
   Google Scholar
• Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71. doi:10.103/nature13954.
   PubMed Web of Science ®Google Scholar
• Weide B, Di Giacomo AM, Fonsatti E, Zitvogel L. Immunologic correlates in the course of treatment with immunomodulating antibodies. Seminars Oncol. 2015;42:448–58. doi:10.105/j.seminoncol.2015.02.016.
   Google Scholar
• Ferrucci PF, Ascierto PA, Pigozzo J, Del Vecchio M, Maio M, Antonini Cappellini GC, Guidoboni M, Queirolo P, Savoia P, Mandalà M, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol. 2016;27:732–8. doi:10.109/annon/mdw016.
   PubMed Web of Science ®Google Scholar
• Viaud S, Théry C, Ploix S, Tursz T, Lapierre V, Lantz O, Zitvogel L, Chaput N. Dendritic cell-derived exosomes for cancer immunotherapy: what's next? Cancer Res. 2010;70:1281–5. doi:10.115/0008-5472.CAN-09-3276.
   PubMed Web of Science ®Google Scholar